Clinical Trial Results:
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone
Summary
|
|
EudraCT number |
2012-000564-14 |
Trial protocol |
BE SE DE IT AT GB DK |
Global end of trial date |
24 Feb 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
30 Apr 2016
|
First version publication date |
30 Apr 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
PIPF-023
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02707640 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
F. Hoffmann-La Roche AG
|
||
Sponsor organisation address |
Grenzacherstrasse 124, Basel, Switzerland, CH-4070
|
||
Public contact |
F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
|
||
Scientific contact |
F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
24 Feb 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
24 Feb 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
24 Feb 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the safety and tolerability of treatment with N-acetylcysteine (NAC) (1800 milligram/day [mg/day]) in subjects with mild to moderate idiopathic pulmonary fibrosis (IPF) with background treatment of pirfenidone therapy.
|
||
Protection of trial subjects |
All study subjects were required to read and sign an Informed Consent Form.
|
||
Background therapy |
Pirfenidone was an oral administration of a dose of at least 1602 mg/day and no more than 2404 mg/day during the wash-out and screening period and for at least 8 weeks prior to randomisation. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
28 Jun 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Sweden: 4
|
||
Country: Number of subjects enrolled |
United Kingdom: 10
|
||
Country: Number of subjects enrolled |
Austria: 1
|
||
Country: Number of subjects enrolled |
Belgium: 6
|
||
Country: Number of subjects enrolled |
Denmark: 7
|
||
Country: Number of subjects enrolled |
France: 28
|
||
Country: Number of subjects enrolled |
Germany: 46
|
||
Country: Number of subjects enrolled |
Italy: 20
|
||
Worldwide total number of subjects |
122
|
||
EEA total number of subjects |
122
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
40
|
||
From 65 to 84 years |
82
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||
Recruitment details |
- | ||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||
Screening details |
Screening details: A total of 123 subjects were enrolled. Total of 122 subjects received at least 1 dose of double-blind study medication, and thus included in the modified intent-to-treat (mITT) population | ||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||
Period 1 title |
Overall Period
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
N–Acetylcysteine (NAC) | ||||||||||||||||||||||||||||||
Arm description |
Subjects randomised to this arm were administered NAC three times daily and a dose of pirfenidone of at least 1602 mg/day for 24 weeks. Subjects were to be on a dose of pirfenidone of at least 1602 mg/day for a minimum of 8 weeks prior to randomisation and were followed until 4 weeks after last study treatment dose. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
N–Acetylcysteine (NAC)
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Fluimucil
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Effervescent tablet
|
||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Subjects received 600 mg NAC effervescent tablets orally three times a day.
|
||||||||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||||||||
Arm description |
Subjects randomised to this arm were administered matching placebo orally three times daily and a dose of pirfenidone of at least 1602 mg/day for 24 weeks. Subjects were to be on a dose of pirfenidone of at least 1602 mg/day for a minimum of 8 weeks prior to randomisation and were followed until 4 weeks after last study treatment dose. | ||||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Effervescent tablet
|
||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Subjects received matching placebo to NAC orally three times a day.
|
||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
N–Acetylcysteine (NAC)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects randomised to this arm were administered NAC three times daily and a dose of pirfenidone of at least 1602 mg/day for 24 weeks. Subjects were to be on a dose of pirfenidone of at least 1602 mg/day for a minimum of 8 weeks prior to randomisation and were followed until 4 weeks after last study treatment dose. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects randomised to this arm were administered matching placebo orally three times daily and a dose of pirfenidone of at least 1602 mg/day for 24 weeks. Subjects were to be on a dose of pirfenidone of at least 1602 mg/day for a minimum of 8 weeks prior to randomisation and were followed until 4 weeks after last study treatment dose. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
N–Acetylcysteine (NAC)
|
||
Reporting group description |
Subjects randomised to this arm were administered NAC three times daily and a dose of pirfenidone of at least 1602 mg/day for 24 weeks. Subjects were to be on a dose of pirfenidone of at least 1602 mg/day for a minimum of 8 weeks prior to randomisation and were followed until 4 weeks after last study treatment dose. | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Subjects randomised to this arm were administered matching placebo orally three times daily and a dose of pirfenidone of at least 1602 mg/day for 24 weeks. Subjects were to be on a dose of pirfenidone of at least 1602 mg/day for a minimum of 8 weeks prior to randomisation and were followed until 4 weeks after last study treatment dose. |
|
|||||||||||||
End point title |
Percentage of Subjects With Dose Reductions [1] | ||||||||||||
End point description |
Percentage of subjects with dose reductions in N-Acetylcysteine and placebo cohorts during the 24-week treatment period. mITT population included subjects who received at least 1 dose of double-blind study medication (NAC or placebo).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
From baseline up to 24 weeks
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be reported. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects with Early Treatment Discontinuations [2] | ||||||||||||
End point description |
Percentage of subjects with early study treatment discontinuations in N-Acetylcysteine and placebo cohorts during the 24-week treatment period. mITT population included subjects who received at least 1 dose of double-blind study medication (NAC or placebo).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
From baseline up to 24 weeks
|
||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be reported. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With Treatment-Emergent Adverse Events (TEAEs) [3] | ||||||||||||
End point description |
An adverse event (AE) is defined as any untoward medical occurrence in a subject who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment. mITT Population included subjects who received at least 1 dose of double-blind study medication (NAC or placebo).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Until 28 days from last dose of study treatment (Week 28)
|
||||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be reported. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With Treatment-Emergent Serious Adverse Events (SAEs) [4] | ||||||||||||
End point description |
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose results in death, is life threatening, requires hospitalization or prolongation of hospitalization, or results in disability/incapacity, or congenital anomaly/birth defect. mITT population included subjects who received at least 1 dose of double-blind study medication (NAC or placebo).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Until 28 days from last dose of study treatment (Week 28)
|
||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be reported. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With Treatment-Emergent Adverse Events Resulting in Permanent Discontinuation of Study Treatment [5] | ||||||||||||
End point description |
mITT population included subjects who received at least 1 dose of double-blind study medication (NAC or placebo).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Until 28 days from last dose of study treatment (Week 28)
|
||||||||||||
Notes [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be reported. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With Treatment-Emergent Deaths of All Causes [6] | ||||||||||||
End point description |
mITT population included who received at least 1 dose of double-blind study medication (NAC or placebo).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Until 28 days from last dose of study treatment (Week 28)
|
||||||||||||
Notes [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be reported. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With Treatment-Emergent Adverse Events That Led to Dose Reduction or Temporary Discontinuation of Study Treatment [7] | ||||||||||||
End point description |
mITT population included who received at least 1 dose of double-blind study medication (NAC or placebo).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Until 28 days from last dose of study treatment (Week 28)
|
||||||||||||
Notes [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be reported. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Until 28 days from last dose of study treatment (Week 28)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
11.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
N–Acetylcysteine (NAC)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects randomised to this arm were administered NAC three times daily and a dose of pirfenidone of at least 1602 mg/day for 24 weeks. Subjects were to be on a dose of pirfenidone of at least 1602 mg/day for a minimum of 8 weeks prior to randomisation and were followed for 4 weeks after last study treatment dose. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects randomised to this arm were administered matching placebo orally three times daily and a dose of pirfenidone of at least 1602 mg/day for 24 weeks. Subjects were to be on a dose of pirfenidone of at least 1602 mg/day for a minimum of 8 weeks prior to randomisation and were followed for 4 weeks after last study treatment dose. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
18 Jun 2014 |
Study sample size estimate was reduced from 125 subjects per arm to allow for an observed exposure of approximately 62.5 subject-years per arm to 60 subjects per arm for an observed exposure of approximately 30 subject-years per arm which was considered reasonably long to detect potential differences of the safety and tolerability of NAC added to background treatment.
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |